Vegzelma (bevacizumab-adcd) - Celltrion, Hikma
Tecentriq (atezolizumab) - Roche
Avzivi (bevacizumab-tnjn) - Bio-Thera Solutions, Cipla, BeOne Medicines, Biomm, Mega Lifesciences, Sandoz
Avastin (bevacizumab) - Roche
Aybintio (bevacizumab biosimilar) - Samsung, 3SBio, Mundipharma
Avegra (bevacizumab biosimilar) - Biocad
ZIABC011078: Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma (clinicaltrials.gov) - Oct 15, 2026 - P2 | N=63 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Oct 2026 ➔ Oct 2027 | Trial primary completion date: Oct 2026 ➔ Oct 2027 
IO biomarker • Trial completion date • Trial primary completion date • Alveolar Soft Tissue Sarcoma • Oncology • Sarcoma • Solid Tumor
http://clinicaltrials.gov/ct2/show/NCT03141684
 
Oct 15, 2026
 
Prev Next